

Théradiol Acquires TauroSept® and Expands Internationally

Théradiol takes a new step in its development by becoming the owner of the TauroSept® lock solution, a reference product in the prevention of central venous catheter-related infections.

With this acquisition, the french company, with over 20 years of experience, confirms its role as a french expert and initiates a new international growth dynamic.

A Strategic Move for Théradiol

Recognized for its commitment in dialysis, parenteral nutrition, gastroenterology, and oncology, Théradiol now becomes the owner of **TauroSept®**.

This flagship product joins **Théradiol's** portfolio, strengthening its position in the vascular access market and opening new opportunities at the European and international levels.

20 Years of Commitment and Trust

Since its founding, Théradiol has established itself as a close partner to healthcare professionals and patients.

David Wemans, Vice President of Regenerative Technologies at Geistlich, says: *"We are delighted to have found such a proven expert in Théradiol who will provide a continued successful future for TauroSept®".*

The integration of **TauroSept®** consolidates this expertise while enabling the company to accelerate its growth, expand its reach, and continue offering reliable, innovative solutions tailored to current clinical challenges.

"This acquisition marks a pivotal moment for our company. It reflects our commitment to providing high-value solutions, both in France and internationally," said Frédéric Le Pottier, President of the Théradiol Group

ABOUT THÉRADIAL

Founded in 1998, Théradiol specializes in the distribution of medical devices and pharmaceuticals, particularly in nephrology, gastroenterology, oncology, and clinical nutrition. As part of the Théradiol Group, alongside the EMA and SINED, Digital Division, the company places proximity to healthcare professionals at the heart of its mission. Guided by its values—innovation, perseverance, listening, and conviviality—Théradiol is fully committed to offering reliable, tailored solutions that support patient care.

ABOUT TAUROSEPT® AND GEISTLICH PHARMA

TauroSept® is a taurolidine-based lock solution used to prevent central venous catheter-related infections. This Class III medical device is effective against a wide range of bacteria and plays a key role in infection prevention, particularly for patients receiving parenteral nutrition or with implanted ports.

Geistlich Pharma AG is a Swiss, family-owned company founded in 1851, specializing in regenerative medicine. It develops and produces biomaterials for bone, cartilage and tissue regeneration and a global leader in regenerative dentistry. Headquartered in Wolhusen, it operates in over 60 countries through 15 affiliates and employs more than 800 people.



Informations :

Discover our video about who we are and our expertise

<https://theradial.com/>


<https://www.geistlich.com/infectiology-professionals/infectiology/geistlich-taurosept>

Contact

Manon Gaudré

Communications and Events Officer

 manon.gaudre@theradial.com

 +336 71 07 23 23